Short‐Term Clinical Effects After Switching From Zinc Acetate Hydrate to Zinc Histidine Hydrate in Patients With Chronic Liver Disease
Hepatology Research · 2026-08 · 56 (8) · 1286-1291
DOI: 10.1111/hepr.70189 ↗At a glance
Journal article in Hepatology Research, published online on 2026-04-18. Written by Yoshihito Uchida and 9 co-authors. Institution: Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan. 15 references. The full text is freely available (open access, CC BY-NC 4.0). Funded by: Nobelpharma Co. Ltd..
Abstract (original language)
Background
Zinc deficiency is common in patients with chronic liver disease and is associated with hepatic encephalopathy, malnutrition, and poor prognosis. Zinc histidine hydrate was recently approved in Japan for the treatment of hypozincemia; however, clinical evidence regarding switching from zinc acetate hydrate remains limited. This study evaluated the short‐term efficacy and safety of switching to zinc histidine hydrate in patients with chronic liver disease.
Methods
This single‐center prospective single‐arm switching study enrolled patients receiving zinc acetate hydrate. Patients were switched to zinc histidine hydrate at an equivalent elemental zinc dose. Serum zinc, ammonia, and copper levels were evaluated at 4 and 12 weeks. Appetite was assessed at baseline and 4 weeks using the Council on Nutrition Appetite Questionnaire Japanese version (CNAQ‐J) and the Functional Assessment of Anorexia/Cachexia Therapy–Anorexia/Cachexia Subscale (FAACT A/CS).
Results
Forty‐two patients were switched to zinc histidine hydrate, and 40 were included in the analysis. The median serum zinc level increased significantly from 83 μg/dL at baseline to 101 μg/dL at 4 weeks ( p = 0.0003) and remained significantly elevated at 96 μg/dL at 12 weeks ( p = 0.0005). Serum ammonia and copper levels showed no significant changes. Appetite‐related scores improved significantly after switching, with increases in CNAQ‐J and FAACT A/CS scores at 4 weeks. No overt hepatic encephalopathy or clinically significant adverse events were observed.
Conclusions
Switching from zinc acetate hydrate to zinc histidine hydrate rapidly increased serum zinc levels and improved appetite. Zinc histidine hydrate may represent a practical option for optimizing zinc supplementation in patients with chronic liver disease.
Subjects
Author keywords
Authors and institutions
- Department of Gastroenterology & Hepatology, Faculty of Medicine, Saitama Medical University, Saitama, Japan.
ORCID profiles: Nobuaki Nakayama, Suguru Mizuno, Satoshi Mochida
Funding
- Nobelpharma Co. Ltd.
Cite
APA
Uchida, Y., Soma, N., Tsuji, S., Ando, S., Sugawara, K., Nakao, M., Nakayama, N., Imai, Y., Mizuno, S., & Mochida, S. (2026). Short‐Term Clinical Effects After Switching From Zinc Acetate Hydrate to Zinc Histidine Hydrate in Patients With Chronic Liver Disease. Hepatology Research, 56(8), 1286-1291. https://doi.org/10.1111/hepr.70189
Vancouver
Uchida Y, Soma N, Tsuji S, Ando S, Sugawara K, Nakao M, et al. Short‐Term Clinical Effects After Switching From Zinc Acetate Hydrate to Zinc Histidine Hydrate in Patients With Chronic Liver Disease. Hepatology Research. 2026;56(8):1286-1291. doi:10.1111/hepr.70189
BibTeX
@article{Uchida2026,
author = {Uchida, Yoshihito and Soma, Naoto and Tsuji, Shohei and Ando, Satsuki and Sugawara, Kayoko and Nakao, Masamitsu and Nakayama, Nobuaki and Imai, Yukinori and Mizuno, Suguru and Mochida, Satoshi},
title = {Short‐Term Clinical Effects After Switching From Zinc Acetate Hydrate to Zinc Histidine Hydrate in Patients With Chronic Liver Disease},
journal = {Hepatology Research},
year = {2026},
volume = {56},
number = {8},
pages = {1286--1291},
doi = {10.1111/hepr.70189}
}
EUVIMED